Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de Buntanetap en participantes con EP

28 de octubre de 2026 actualizado por: Annovis Bio Inc.

Un ensayo clínico abierto que investiga la seguridad a largo plazo de Buntanetap en el tratamiento de participantes con enfermedad de Parkinson

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days. MMSE, MoCA, C-SSRS, and MDS-UPDRS will be assessed by clinicians who have successfully completed the requisite certifications/trainings for each assessment. Each participant shall be assessed by the same clinician throughout the study. Cohort 1 participants will stop standard of care Parkinson's medications 12h before baseline and annual clinical visits to ensure clinical OFF-state during visit. Cohort 2 participants will stop standard of care Parkinson's medications 12h before all clinic visits. The night before the baseline and annual clinic visits (or early termination visit), Cohort 2 participants will return DBS settings to their initial baseline settings.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

500

Fase

  • Fase 2
  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • Reclutamiento
        • University of Alabama at Birmingham
        • Contacto:
        • Investigador principal:
          • Natividad Stover, M.D.
    • Arizona
      • Sun City, Arizona, Estados Unidos, 85351
        • Reclutamiento
        • Banner Sun Health Research Institute - Cleo Roberts Center for Clinical Research
        • Investigador principal:
          • Sara Dhanani, M.D.
        • Contacto:
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • Reclutamiento
        • Parkinson's & Movement Disorder Institute (PMDI) - Orange County Office
        • Investigador principal:
          • Daniel Truong, M.D.
        • Contacto:
          • Evan Moreno-Davis
          • Número de teléfono: 714-378-5074
          • Correo electrónico: evan@pmdi.org
    • Colorado
      • Englewood, Colorado, Estados Unidos, 80113
        • Reclutamiento
        • Cenexel Rocky Mountain Clinical Research
        • Contacto:
        • Investigador principal:
          • Meagen Salinas, M.D.
    • Connecticut
      • Stamford, Connecticut, Estados Unidos, 06824
        • Reclutamiento
        • New England Institute for Clinical Research (Ki Health Partners)
        • Contacto:
          • Valerija Misev
          • Número de teléfono: 125 203-914-1903
          • Correo electrónico: Valerija@neinh.com
        • Investigador principal:
          • Peter McAllister, M.D.
    • Florida
      • Aventura, Florida, Estados Unidos, 33180
        • Reclutamiento
        • First Choice Neurology - Aventura Neurologic Associates
        • Investigador principal:
          • Jonathan Cross, M.D.
        • Contacto:
      • Daytona Beach, Florida, Estados Unidos, 32117
        • Reclutamiento
        • Arrow Clinical Trials
        • Contacto:
        • Investigador principal:
          • David Billmeier, M.D.
      • DeLand, Florida, Estados Unidos, 32720
        • Reclutamiento
        • Accel Clinical Sites-Georgia LLC dba Accel Research Sites-Lake Oconee CRU
        • Investigador principal:
          • Bruce Rankin, D.O.
        • Contacto:
      • Miami, Florida, Estados Unidos, 33172
      • Miami, Florida, Estados Unidos, 33015
        • Aún no reclutando
        • Ezy Medical Research Co.
        • Contacto:
      • Ocala, Florida, Estados Unidos, 34470
        • Reclutamiento
        • Renstar Medical Research
        • Investigador principal:
          • Annette Nieves, M.D.
        • Contacto:
      • Tampa, Florida, Estados Unidos, 33613
        • Reclutamiento
        • University of South Florida (USF) - University of South Florida College of Medicine - Parkinson's Di
        • Contacto:
        • Investigador principal:
          • Robert Hauser, M.D., MBA
      • Winter Park, Florida, Estados Unidos, 32789
        • Reclutamiento
        • Conquest Research
        • Contacto:
        • Investigador principal:
          • Rekha Gandhi, M.D.
    • Georgia
      • Decatur, Georgia, Estados Unidos, 30030
        • Reclutamiento
        • iResearch Atlanta
        • Contacto:
        • Investigador principal:
          • Kimball Johnson, M.D.
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Reclutamiento
        • Josephson Wallack Munshower Neurology, P.C.
        • Investigador principal:
          • Kristi George, M.D.
        • Contacto:
    • Kansas
      • Kansas City, Kansas, Estados Unidos, 66160
        • Reclutamiento
        • University of Kansas Medical Center (KUMC) - School of Medicine - Parkinson's Disease and Movement D
        • Contacto:
          • Kelly Lyons
          • Número de teléfono: 913-588-7159
          • Correo electrónico: klyons@kumc.edu
        • Investigador principal:
          • Rajesh Pahwa, M.D.
    • Michigan
      • Farmington Hills, Michigan, Estados Unidos, 48334
        • Reclutamiento
        • Quest Research Institute
        • Investigador principal:
          • Aaron Ellenbogen, D.O.
        • Contacto:
    • New York
      • New York, New York, Estados Unidos, 10019
        • Reclutamiento
        • Mount Sinai Hospital
        • Investigador principal:
          • Joohi Jimenez-Shahed, M.D.
        • Contacto:
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Reclutamiento
        • Duke Department of Neurosurgery
        • Investigador principal:
          • Kyle Mitchell, M.D.
        • Contacto:
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Reclutamiento
        • The Ohio State University Wexner Medical Center
        • Investigador principal:
          • Zachary Jordan, M.D.
        • Contacto:
    • Oklahoma
      • Tulsa, Oklahoma, Estados Unidos, 74136
        • Reclutamiento
        • The Movement Disorder Clinic of Oklahoma
        • Contacto:
        • Investigador principal:
          • Kevin Klos, M.D.
    • Pennsylvania
      • Willow Grove, Pennsylvania, Estados Unidos, 19090
        • Reclutamiento
        • Abington Neurology
        • Investigador principal:
          • David Weisman, M.D.
        • Contacto:
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29401
        • Reclutamiento
        • Medical University of South Carolina (MUSC) - The Murray Center for Research on Parkinson's Disease
        • Contacto:
          • Sandra Wilson
          • Número de teléfono: 843-792-3223
          • Correo electrónico: wilsosan@musc.edu
        • Investigador principal:
          • Vanessa Hinson, M.D., PhD
    • Tennessee
      • Cordova, Tennessee, Estados Unidos, 38018
        • Reclutamiento
        • Neurology Clinic, P.C.
        • Contacto:
        • Investigador principal:
          • Kendrick Henderson, M.D.
      • Memphis, Tennessee, Estados Unidos, 38157
        • Reclutamiento
        • Veracity Neuroscience LLC
        • Contacto:
        • Investigador principal:
          • Mark LeDoux, M.D., PhD
    • Texas
      • Round Rock, Texas, Estados Unidos, 78681
        • Reclutamiento
        • Central Texas Neurology
        • Contacto:
        • Investigador principal:
          • Elizabeth Peckham, M.D.
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22903
        • Reclutamiento
        • University of Virginia Health System (UVAHS) - Adult Neurology Clinic
        • Investigador principal:
          • Binit Shah, M.D.
        • Contacto:
    • Washington
      • Spokane, Washington, Estados Unidos, 99202
        • Reclutamiento
        • Inland Northwest Research
        • Investigador principal:
          • Jason Aldred, M.D.
        • Contacto:
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Reclutamiento
        • Medical College of Wisconsin
        • Contacto:
          • Shelby Schold
          • Número de teléfono: 414-955-0698
          • Correo electrónico: sschold@mcw.edu
        • Investigador principal:
          • Karen Blindauer, M.D.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años a 85 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015) and

    a. Cohort 1: Participated in a prior PD clinical trial with buntanetap. i. A legally authorized representative is required for any participant whose MMSE <21 at screening.

    b. Cohort 2: Has been receiving DBS treatment in either 1) the subthalamic nucleus or 2) the globus pallidus internus for at least 12 months after a successful DBS surgery that achieved the goal.

    i. Female or male adults aged 40 to 85 years. ii. H&Y stage 1-3 in ON state. iii. MMSE 21-30 at screening and baseline.

  2. Have a support person who will accompany the participant on study visits at designated times.

  3. Female participants of childbearing potential* must have a negative urine pregnancy test at screening, must be non-lactating, and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for one month after the last dose of trial treatment, such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,

    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,

    3. Intrauterine device (IUD),

    4. Intrauterine hormone-releasing system (IUS),

    5. Bilateral tubal occlusion,

    6. Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used),

    7. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant).

      • Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 30 of 54

  4. Male participants must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male participants must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    1. Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation,
    2. Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation,
    3. IUD,
    4. IUS,
    5. Bilateral tubal occlusion.
  5. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the C-SSRS.

  6. Stability of permitted medications for at least 4 weeks prior to screening. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

    1. Standard of care anti-parkinsonian medication,
    2. Cholinesterase inhibitors and/or memantine medication,
    3. Anticonvulsant medications used for epilepsy or mood stabilization, or neuropathic pain indications, and have not had a breakthrough seizure 3 years prior to screening,
    4. Mood-stabilizing psychotropic agents including, but not limited to, lithium,
  7. Adequate visual and hearing ability (physical ability to perform all the study assessments).

  8. Good general health with no disease expected to interfere with the study.

Exclusion Criteria:

  1. Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in Cohort 2 if they meet the corresponding inclusion/exclusion criteria).

  2. A history of psychiatric disorder such as schizophrenia, bipolar disorder, or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM), unless their symptoms have been mild, and they are stable on treatment or no longer need treatment. Mild depression or history of depression that is stable on treatment with selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI) medication at a stable dose is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  3. A history of seizure disorder. If stable on medication, it is acceptable. Refer to Concomitant Medications section above for details on prohibited and permitted medications.

  4. A history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 450 ms for men and ≥ 460 ms for women, or torsades de pointes.

  5. Bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening and deemed medically significant by the PI.

    Protocol ANVS-25002 Ver. 2.1; 09-23-2025 Confidential Page 31 of 54

  6. Uncontrolled Type-1 or Type-2 diabetes. A participant with hemoglobin subunit alpha 1c (HbA1c) levels up to 7.5% can be enrolled if the investigator believes the participant's diabetes is under control.

  7. Clinically significant renal (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] <50 mL/min/BSA [body surface area]) or hepatic impairment (Alkaline phosphatase [ALP] > 2.0X the upper limit of normal [ULN] and/or total bilirubin > 2.0X ULN).

  8. Any clinically significant abnormal laboratory values. Participants with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice ULN will be excluded.

  9. Is at imminent risk of self-harm, based on clinical interview and responses on the C-SSRS, or of harm to others in the opinion of the investigators. Participants must be excluded if they report suicidal ideation with intent, with or without a plan or method (e.g., positive response to Items 4 or 5 in assessment of suicidal ideation on C-SSRS) in the past 2 months, or suicidal behavior in the past 6 months.

  10. Cancer or has had a malignant tumor within the past year, except participants who underwent potentially curative therapy with no evidence of recurrence (participants with stable untreated cancer are not excluded).

  11. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version of the DSM.

  12. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken.

  13. A learning disability or developmental delay.

  14. Participants whom the site PI deems to be otherwise ineligible.

  15. A known allergy to the investigational drug or any of its components.

    Inactive ingredients of the investigational medicinal product:

    • Silicified microcrystalline cellulose
    • Dibasic calcium phosphate dihydrate
    • Mannitol
    • Stearic acid
    • Hypromellose (capsule shells structure)
    • Titanium dioxide (opacifier of the capsule shells)
  16. Is currently pregnant, breast-feeding, and/or lactating.

  17. Uncontrolled hypertension (systolic >160mmHg and/or diastolic >95mmHg) or hypotension (systolic <90mmHg and/or diastolic <60 mmHg) and deemed medically significant by the PI.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohort 1 - buntanetap

Cohort 1 will enroll via invitation only for PD participants who have previously participated in bun

buntanetap capsules 30 mg by mouth daily

Experimental: Cohort 2 - buntanetap

Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment.

buntanetap capsules 30 mg by mouth daily

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety of buntanetap
Periodo de tiempo: 36-months of treatment

Safety assessments of participants with PD receiving treatment with buntanetap

36-months of treatment
Adverse Events (AE)
Periodo de tiempo: 36-months of treatment

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

36-months of treatment
Treatment Emergent Adverse Events (TEAE)
Periodo de tiempo: 36-months of treatment

TEAE is an event that emerges during treatment, having been absent pretreatment, or worsens relative to the pretreatment state

36-months of treatment
Serious Adverse Events (SAE)
Periodo de tiempo: 36-months of treatment

SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a birth defect or congenital anomaly

36-months of treatment

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Laurie Sanders, Ph.D., Duke Clinical Research Institute

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de enero de 2026

Finalización primaria (Estimado)

1 de septiembre de 2029

Finalización del estudio (Estimado)

1 de noviembre de 2029

Fechas de registro del estudio

Enviado por primera vez

26 de noviembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

9 de diciembre de 2025

Publicado por primera vez (Actual)

16 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir